EP1549598A4 - Napththalene derivatives which inhibit the cytokine or biological activity of macrophage migration inhibitory factor (mif) - Google Patents
Napththalene derivatives which inhibit the cytokine or biological activity of macrophage migration inhibitory factor (mif)Info
- Publication number
- EP1549598A4 EP1549598A4 EP03724672A EP03724672A EP1549598A4 EP 1549598 A4 EP1549598 A4 EP 1549598A4 EP 03724672 A EP03724672 A EP 03724672A EP 03724672 A EP03724672 A EP 03724672A EP 1549598 A4 EP1549598 A4 EP 1549598A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- napththalene
- mif
- cytokine
- inhibit
- derivatives
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
- A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C205/00—Compounds containing nitro groups bound to a carbon skeleton
- C07C205/49—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by carboxyl groups
- C07C205/57—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by carboxyl groups having nitro groups and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
- C07C205/59—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by carboxyl groups having nitro groups and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton the carbon skeleton being further substituted by singly-bound oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/52—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
- C07C229/68—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings being part of the same condensed ring system
- C07C229/70—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings being part of the same condensed ring system the carbon skeleton being further substituted by singly-bound oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
- C07C255/32—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring
- C07C255/37—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by etherified hydroxy groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C309/57—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing carboxyl groups bound to the carbon skeleton
- C07C309/60—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing carboxyl groups bound to the carbon skeleton the carbon skeleton being further substituted by singly-bound oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/63—Esters of sulfonic acids
- C07C309/72—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C309/75—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing singly-bound oxygen atoms bound to the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C333/00—Derivatives of thiocarbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C333/02—Monothiocarbamic acids; Derivatives thereof
- C07C333/04—Monothiocarbamic acids; Derivatives thereof having nitrogen atoms of thiocarbamic groups bound to hydrogen atoms or to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C43/00—Ethers; Compounds having groups, groups or groups
- C07C43/02—Ethers
- C07C43/20—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring
- C07C43/225—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring containing halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C43/00—Ethers; Compounds having groups, groups or groups
- C07C43/02—Ethers
- C07C43/20—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring
- C07C43/23—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring containing hydroxy or O-metal groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
- C07C45/004—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reaction with organometalhalides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
- C07C45/45—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by condensation
- C07C45/46—Friedel-Crafts reactions
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/40—Unsaturated compounds
- C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C65/21—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing ether groups, groups, groups, or groups
- C07C65/24—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing ether groups, groups, groups, or groups polycyclic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C65/21—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing ether groups, groups, groups, or groups
- C07C65/28—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing ether groups, groups, groups, or groups having unsaturation outside the aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/76—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring
- C07C69/94—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring of polycyclic hydroxy carboxylic acids, the hydroxy groups and the carboxyl groups of which are bound to carbon atoms of six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D235/26—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
- C07D307/83—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
- C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
- C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D319/18—Ethylenedioxybenzenes, not substituted on the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
- C07H13/02—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
- C07H13/10—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals directly attached to heterocyclic rings
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AUPS2834A AUPS283402A0 (en) | 2002-06-07 | 2002-06-07 | Combination therapy |
AUPS2833A AUPS283302A0 (en) | 2002-06-07 | 2002-06-07 | Therapeutic molecules and methods - 2 |
AUPS283402 | 2002-06-07 | ||
AUPS283302 | 2002-06-07 | ||
PCT/AU2003/000716 WO2003104178A1 (en) | 2002-06-07 | 2003-06-06 | Napththalene derivatives which inhibit the cytokine or biological activity of macrophage migration inhibitory factor (mif) |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1549598A1 EP1549598A1 (en) | 2005-07-06 |
EP1549598A4 true EP1549598A4 (en) | 2008-01-23 |
Family
ID=29737415
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP03724672A Withdrawn EP1549598A4 (en) | 2002-06-07 | 2003-06-06 | Napththalene derivatives which inhibit the cytokine or biological activity of macrophage migration inhibitory factor (mif) |
Country Status (9)
Country | Link |
---|---|
US (1) | US20060106102A1 (en) |
EP (1) | EP1549598A4 (en) |
JP (1) | JP2006511445A (en) |
CN (1) | CN1675154A (en) |
AU (1) | AU2003229142A1 (en) |
CA (1) | CA2487866A1 (en) |
GB (1) | GB2405146A (en) |
IL (1) | IL165537A0 (en) |
WO (1) | WO2003104178A1 (en) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MY140679A (en) | 2001-05-24 | 2010-01-15 | Avanir Pharmaceuticals | Inhibitors of macrohage migration inhibitory factor and methods for identifying the same |
TW200418829A (en) | 2003-02-14 | 2004-10-01 | Avanir Pharmaceutics | Inhibitors of macrophage migration inhibitory factor and methods for identifying the same |
JP2007503388A (en) | 2003-08-22 | 2007-02-22 | アバニール・ファーマシューティカルズ | Substituted naphthyridine derivatives as inhibitors of macrophage migration inhibitory factor and their use in the treatment of human diseases |
WO2005058304A1 (en) * | 2003-12-17 | 2005-06-30 | Cortical Pty Ltd | Implantable device containing inhibitor of macrophage migration inhibitory factor |
WO2005087210A2 (en) | 2004-03-17 | 2005-09-22 | Lars Michael Larsen | Prevention of retinopathy by inhibition of the visual cycle |
WO2006102191A1 (en) | 2005-03-24 | 2006-09-28 | Avanir Pharmaceuticals | Thienopyridinone derivatives as macrophage migration inhibitory factor inhibitors |
US7915285B2 (en) | 2005-09-26 | 2011-03-29 | The Regents Of The University Of Colorado | Method for treating drug and behavioral addictions |
ES2279730B1 (en) * | 2006-02-14 | 2008-08-01 | Italfarmaco, S.A. | USE OF SULFONIC ACID DERIVATIVES IN THE TREATMENT OF OCULAR VASOPROLIFERATIVE DISEASES. |
WO2007142924A1 (en) * | 2006-05-31 | 2007-12-13 | Avigen, Inc. | Ibudilast for inhibiting macrophage migration inhibitory factor (mif) activity |
WO2007142923A1 (en) * | 2006-05-31 | 2007-12-13 | Avigen, Inc. | Mif inhibitors for treating neuropathic pain and associated syndromes |
ATE509925T1 (en) | 2006-11-17 | 2011-06-15 | Pfizer | SUBSTITUTED BICYCLOCARBONIC ACID AMIDE COMPOUNDS |
US9540322B2 (en) | 2008-08-18 | 2017-01-10 | Yale University | MIF modulators |
US9643922B2 (en) | 2008-08-18 | 2017-05-09 | Yale University | MIF modulators |
SG181702A1 (en) | 2009-12-16 | 2012-07-30 | Pola Chem Ind Inc | Preventing or ameliorating agent for pigmentation |
JP6509112B2 (en) * | 2012-07-03 | 2019-05-08 | プラブダ,ジェイ | Methods for the treatment, diagnosis and / or monitoring of the progression of oxo related conditions |
JP6615753B2 (en) * | 2013-10-04 | 2019-12-04 | レジニアス リミテッド | Biomarkers for cell therapy |
CN104958285A (en) * | 2015-06-10 | 2015-10-07 | 江琴 | Non-small cell lung cancer resistant medicinal composition and an application thereof |
WO2018138050A1 (en) | 2017-01-26 | 2018-08-02 | Bayer Aktiengesellschaft | Condensed bicyclic heterocyclene derivatives as pest control agents |
JP7158420B2 (en) * | 2017-02-24 | 2022-10-21 | アルツェオン・インコーポレーテッド | Methods for treating neurodegenerative disorders |
CN108863775B (en) * | 2018-05-07 | 2022-05-03 | 常州佳德医药科技有限公司 | Preparation method of 6-hydroxy-1-naphthoic acid |
CN111533718B (en) * | 2020-05-12 | 2022-05-17 | 浙江海洲制药有限公司 | Method for preparing benzbromarone |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4297372A (en) * | 1978-12-20 | 1981-10-27 | American Cyanamid Company | Ureide inhibitors of connective tissue destruction |
WO1985004099A1 (en) * | 1984-03-21 | 1985-09-26 | Key Pharmaceuticals, Inc. | Sustained release oral dosage form for naproxyn |
US4681894A (en) * | 1986-09-26 | 1987-07-21 | Ortho Pharmaceutical Corporation | Hydroxamic acids and esters |
US5194446A (en) * | 1989-06-12 | 1993-03-16 | A. H. Robins Company, Incorporated | Compounds having one or more aminosulfaonyloxy radicals useful as pharmaceuticals |
WO1996020187A2 (en) * | 1994-12-23 | 1996-07-04 | Alcon Laboratories, Inc. | Esters and amides of non-steroidal anti-inflammatory carboxylic acids which may be used as anti-oxidants, 5-lipoxygenase inhibitors and non-steroidal anti-inflammatory products |
US5756125A (en) * | 1992-08-31 | 1998-05-26 | G. D. Searle & Co. | Controlled release naproxen sodium plus naproxen combination tablet |
US5962531A (en) * | 1997-01-28 | 1999-10-05 | Syntex (U.S.A.) Inc. | 5-aroylnaphthalene derivatives as anti-inflammatory agents |
Family Cites Families (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4009197A (en) * | 1967-01-13 | 1977-02-22 | Syntex Corporation | 2-(6-Substituted-2'-naphthyl) acetic acid derivatives and the salts and esters thereof |
US3904682A (en) * | 1967-01-13 | 1975-09-09 | Syntex Corp | 2-(6{40 -Methoxy-2{40 -naphthyl)acetic acid |
CA960689A (en) * | 1967-01-13 | 1975-01-07 | Syntex Corporation | 2-naphthyl acetic acid derivatives and compositions |
NL6809942A (en) * | 1968-07-12 | 1970-01-14 | 2-Naphthyl-acetic acid derivs. - useful as antiinflammatory, analgesic, antipyretic and anti:pruritc agents | |
US3562336A (en) * | 1968-07-24 | 1971-02-09 | Syntex Corp | Synthesis of naphthalene derivatives |
DE2051012A1 (en) * | 1970-10-17 | 1972-04-20 | Syntex Corp., Panama | 1,6-methano-(10)-annulenes - with anti-inflammatory analgesic antipyr hypocholesterolaemic and fibrinolytic activity |
US3978124A (en) * | 1971-11-04 | 1976-08-31 | Syntex Corporation | 6-Substituted 2-naphthyl α-substituted acetamides |
US3998966A (en) * | 1971-11-04 | 1976-12-21 | Syntex Corporation | Anti-inflammatory, analgesic, anti-pyretic and anti-pruritic 6-substituted 2-naphthyl acetic acid derivative-containing compositions and methods of use thereof |
US3969415A (en) * | 1971-12-01 | 1976-07-13 | Sandoz, Inc. | 1-(2-Naphthyl)-2,3-butadien-1-ols |
BE792079A (en) * | 1971-12-01 | 1973-05-29 | Sandoz Sa | NEW INSATURE COMPOUNDS, THEIR PREPARATION AND THEIR APPLICATION AS MEDICINAL PRODUCTS |
US3935273A (en) * | 1972-01-31 | 1976-01-27 | Syntex Corporation | Naphthyl acetaldehyde derivatives |
FR2187319B1 (en) * | 1972-06-09 | 1975-06-20 | Bottu Exploit Labo | |
US3958012A (en) * | 1972-10-27 | 1976-05-18 | Syntex Corporation | D 2-(6-Substituted-2-naphthyl)-propanals |
GB1474377A (en) * | 1973-09-11 | 1977-05-25 | Beecham Group Ltd | Naphthalene derivatives |
US3959395A (en) * | 1974-12-26 | 1976-05-25 | Monsanto Company | Recovery of polymerization inhibitor |
US3994968A (en) * | 1975-01-10 | 1976-11-30 | Syntex Corporation | 2-(5'-Halo-6'-methoxynaphth-2'-yl)-acrylic acid |
JPS52133962A (en) * | 1976-04-30 | 1977-11-09 | Grelan Pharmaceut Co Ltd | Synthesis of 2-(6-methoxy-2-naphthyl)-propionic acid |
DE3469169D1 (en) * | 1983-04-21 | 1988-03-10 | Merck Frosst Canada Inc | Leukotriene antagonists, their production and use and compositions containing them |
CA1285951C (en) * | 1985-10-28 | 1991-07-09 | Raj N. Misra | Naphthalenyl- and quinolinyl-amino substituted phenols |
JPS62103074A (en) * | 1985-10-29 | 1987-05-13 | Hamari Yakuhin Kogyo Kk | Production of 2-(6-methoxy-2-naphthyl)-1,2-epoxypropane |
JPS63203631A (en) * | 1987-02-19 | 1988-08-23 | Nippon Kayaku Co Ltd | Production of alpha-arylpropionic acid |
US4767776A (en) * | 1987-02-20 | 1988-08-30 | Warner-Lambert Company | N-1H-tetrazol-5-yl-2-naphthalene carboxamides and their use as antiallergy and antiinflammatory agents |
IL85700A0 (en) * | 1987-03-24 | 1988-08-31 | Takeda Chemical Industries Ltd | 1,4-disubstituted piperazine compounds,their production and use |
IT1216929B (en) * | 1987-04-16 | 1990-03-14 | Enichem Sintesi | PROCEDURE FOR THE SYNTHESIS OF 2-ARYL-PROPIONIC ACIDS. |
AU611699B2 (en) * | 1987-07-31 | 1991-06-20 | American Home Products Corporation | Naphthalene propionic acid derivatives |
US5208344A (en) * | 1987-07-31 | 1993-05-04 | American Home Products Corporation | Naphthalenepropionic acid derivatives as anti-inflammatory/antiallergic agents |
US5084575A (en) * | 1987-07-31 | 1992-01-28 | American Home Products Corporation | Quinoline substituted naphthalenepropionic acid derivatives as anti-inflammatory/antiallergic agents |
JPS6476063A (en) * | 1987-09-18 | 1989-03-22 | Dainichiseika Color Chem | Electrophotographic sensitive body |
US4937373A (en) * | 1988-12-08 | 1990-06-26 | Hoffmann-La Roche Inc. | Substituted naphthalene carboxylic acids |
US5032588A (en) * | 1989-12-08 | 1991-07-16 | Abbott Laboratories | Thiazole lipoxygenase-inhibiting compounds derived from non-steroidal antiinflammatory carboxylic acids |
DE3943286A1 (en) * | 1989-12-29 | 1991-07-04 | Hoechst Ag | AZO COMPOUNDS, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE AS A DYE |
US5837689A (en) * | 1993-06-16 | 1998-11-17 | Glycomed Incorporated | Sialyl lewis-x mimetics containing naphthyl backbones |
ES2103181B1 (en) * | 1994-08-01 | 1998-04-01 | Menarini Lab | NAFTALENIC AMIDES WITH ANTAGONIST ACTION OF THE LEUKOTRENEES. |
US6011029A (en) * | 1996-02-26 | 2000-01-04 | Bristol-Myers Squibb Company | Inhibitors of farnesyl protein transferase |
CA2206997A1 (en) * | 1996-07-10 | 1998-01-10 | Eli Lilly And Company | Benzothiophene compounds and methods of use |
CN1251577A (en) * | 1997-02-21 | 2000-04-26 | 武田药品工业株式会社 | Fused ring compounds, process for producing same and use thereof |
AU8224998A (en) * | 1997-07-04 | 1999-01-25 | Nycomed Amersham Plc | Peroxidase-catalysed fluorescence |
ES2150848B1 (en) * | 1998-04-15 | 2001-07-01 | Menarini Lab | HETEROCICLES METILOXINAFTIL SUBSTITUTED WITH ANTAGONIST ACTION OF LEUCOTRIENOS. |
AU2108601A (en) * | 1999-12-15 | 2001-06-25 | Axys Pharmaceuticals, Inc. | Salicylamides as serine protease inhibitors |
WO2004014377A1 (en) * | 2002-08-13 | 2004-02-19 | Warner-Lambert Company Llc | 4-hydroxyquinoline derivatives as matrix metalloproteinase inhibitors |
-
2003
- 2003-06-06 JP JP2004511248A patent/JP2006511445A/en active Pending
- 2003-06-06 WO PCT/AU2003/000716 patent/WO2003104178A1/en not_active Application Discontinuation
- 2003-06-06 GB GB0427241A patent/GB2405146A/en not_active Withdrawn
- 2003-06-06 EP EP03724672A patent/EP1549598A4/en not_active Withdrawn
- 2003-06-06 CA CA002487866A patent/CA2487866A1/en not_active Abandoned
- 2003-06-06 US US10/517,240 patent/US20060106102A1/en not_active Abandoned
- 2003-06-06 CN CNA038189364A patent/CN1675154A/en active Pending
- 2003-06-06 AU AU2003229142A patent/AU2003229142A1/en not_active Abandoned
-
2004
- 2004-12-02 IL IL16553704A patent/IL165537A0/en unknown
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4297372A (en) * | 1978-12-20 | 1981-10-27 | American Cyanamid Company | Ureide inhibitors of connective tissue destruction |
WO1985004099A1 (en) * | 1984-03-21 | 1985-09-26 | Key Pharmaceuticals, Inc. | Sustained release oral dosage form for naproxyn |
US4681894A (en) * | 1986-09-26 | 1987-07-21 | Ortho Pharmaceutical Corporation | Hydroxamic acids and esters |
US5194446A (en) * | 1989-06-12 | 1993-03-16 | A. H. Robins Company, Incorporated | Compounds having one or more aminosulfaonyloxy radicals useful as pharmaceuticals |
US5756125A (en) * | 1992-08-31 | 1998-05-26 | G. D. Searle & Co. | Controlled release naproxen sodium plus naproxen combination tablet |
WO1996020187A2 (en) * | 1994-12-23 | 1996-07-04 | Alcon Laboratories, Inc. | Esters and amides of non-steroidal anti-inflammatory carboxylic acids which may be used as anti-oxidants, 5-lipoxygenase inhibitors and non-steroidal anti-inflammatory products |
US5962531A (en) * | 1997-01-28 | 1999-10-05 | Syntex (U.S.A.) Inc. | 5-aroylnaphthalene derivatives as anti-inflammatory agents |
Non-Patent Citations (5)
Title |
---|
A. KOJ: "Termination of acute-phase response: role of some cytokines and anti-inflammatory drugs", GENERAL PHARMACOLOGY, vol. 31, no. 1, 1998, pages 9 - 18, XP002461928 * |
KRUG ET AL: "Tolerability and efficacy of nabumetone and naproxen in the treatment of rheumatoid arthritis", CLINICAL THERAPEUTICS, EXCERPTA MEDICA, PRINCETON, NJ, US, vol. 22, no. 1, January 2000 (2000-01-01), pages 40 - 52, XP005508903, ISSN: 0149-2918 * |
M. LEECH ET AL.: "Macrophage migration inhibitory factor in rheumatoid arthritis", ARTHRITIS & RHEUMATISM, vol. 42, no. 8, August 1999 (1999-08-01), pages 1601 - 1608, XP002461927 * |
See also references of WO03104178A1 * |
WIEBALCK ET AL: "2a NSAIDs and other non-opioids in chronic pain", BAILLIERE'S CLINICAL ANAESTHESIOLOGY, BAILLIERE TINDALL, PHILADELPHIA, US, vol. 12, no. 1, March 1998 (1998-03-01), pages 19 - 38, XP005119211, ISSN: 0950-3501 * |
Also Published As
Publication number | Publication date |
---|---|
GB0427241D0 (en) | 2005-01-12 |
GB2405146A (en) | 2005-02-23 |
AU2003229142A1 (en) | 2003-12-22 |
CA2487866A1 (en) | 2003-12-18 |
CN1675154A (en) | 2005-09-28 |
IL165537A0 (en) | 2006-01-15 |
WO2003104178A1 (en) | 2003-12-18 |
US20060106102A1 (en) | 2006-05-18 |
JP2006511445A (en) | 2006-04-06 |
EP1549598A1 (en) | 2005-07-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL165537A0 (en) | Napththalene derivatives which inhibit the cytokine or biological activity of macrophage migration inhibitory factor (MIF) | |
ITBO20020224A0 (en) | STABILIZING SUPPORT FOR ADDITION AND SUBTRACTION OSTEOTOMIES | |
MXPA03008484A (en) | Aryl and biaryl compounds having mch modulatory activity. | |
HK1099014A1 (en) | Malonamide derivatives blocking the activity of gama-secretase | |
SI1583763T1 (en) | Benzoazolylpiperazine derivatives having vr1-antagonist activity | |
AU2003264427A1 (en) | Isoquinoline derivatives having kinasae inhibitory activity and drugs containing the same | |
AU2003220474A1 (en) | Measuring blood flow rate or cardiac output | |
ZA200309738B (en) | Inhibitors of macrophage migration inhibitory factor and methods for identifying the same. | |
AU2002320185A1 (en) | Biological activity of ak155 | |
DE60322507D1 (en) | CONTROLLABLE CATHETER OR THE LIKE | |
NO20051503D0 (en) | Pyrazolopyridines and processes for the preparation and use of the same. | |
DK1534248T3 (en) | The lasofoxy tablet and its coatings | |
EP1573045A4 (en) | Heart failure gene determination and therapeutic screening | |
FI20022225A0 (en) | Setting the heart rate limit on the heart rate monitor | |
IL163823A0 (en) | Indolamid derivatives which possess glycogen phorylase inhibitory activity | |
PL1658037T3 (en) | Method of treatment and bioassay involving macrophage migration inhibitory factor (mif) as cardiac-derived myocardial depressant factor | |
DK1456404T3 (en) | Method for determining the biological activity of difibrotide | |
NO20035056D0 (en) | Adenosine analogues for the treatment of insulin resistance syndrome and diabetes | |
NO20033228L (en) | Use of IL-18 inhibitors for the treatment and / or prevention of heart disease | |
AU2003265420A1 (en) | Polypeptide multimers having antiviral activity | |
ZA200409844B (en) | Napththalene derivatives which inhibit the cytokine or biological activity of macrophage migration inhibitory factor (MIF). | |
NO20021305D0 (en) | DNA construction and its use | |
AU2003233274A1 (en) | Case or chest bed | |
NO20041295L (en) | Tieno (1,3) oxazin-4-ones with lipase inhibitory activity | |
EP1574575A4 (en) | GLUCOSE AND/OR FRUCTOSE TRANSPORTER NaGLT1 AND ITS GENE |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20041206 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR |
|
AX | Request for extension of the european patent |
Extension state: AL LT LV MK |
|
DAX | Request for extension of the european patent (deleted) | ||
A4 | Supplementary search report drawn up and despatched |
Effective date: 20071221 |
|
RTI1 | Title (correction) |
Free format text: NAPHTHALENE DERIVATIVES WHICH INHIBIT THE CYTOKINE OR BIOLOGICAL ACTIVITY OF MACROPHAGE MIGRATION INHIBITORY FACTOR (MIF) |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN |
|
18W | Application withdrawn |
Effective date: 20080606 |